Articles tagged "HLA antibodies"

2018 American Transplant Congress
Pilot Study of Plasma Cell Niche-Targeted Therapy for Enhancement of Proteasome Inhibitor Effectiveness
S. Tremblay,¹ C. Castro-Rojas,² J. Driscoll,¹ S. Knechtle,³ A. Shields,¹ R. Alloway,¹ H. Singh,² D. Hildeman,² E. Woodle.¹
¹UCincinnati, Cincinnati; ²Cincinnati Children's, Cincinnati; ³Duke, Durham.
HLA antibody (Ab)-secreting bone marrow (BM) plasma cell (PC) survival depends on niche occupancy via a CXCR4 (PC)-CXCL12 (BM stromal cell) interaction. Plerixafor inhibits CXCR4-CXCL12…
2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
A. Jackson,¹ B. Iglehart,¹ S. Bagnasco,³ N. Desai.²
¹Medicine, Johns Hopkins University, Baltimore, MD; ²Surgery, Johns Hopkins University, Baltimore, MD; ³Pathology, Johns Hopkins University, Baltimore, MD.
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…
2018 American Transplant Congress
Non Active Desensitization Protocol: Improving Access to Kidney Transplant for Hyperimmunized Patients
S. Le Bot,¹ F. Delbos,² C. Garandeau,¹ S. Malard Castagnet,² A. Cesbron,² M. Hourmant.¹
¹Nephrology and Transplantation, CHU Hôtel Dieu, Nantes, France; ²Laboratoire HLA, Etablissement Français du Sang, Nantes, France.
Hyperimmunized patients have a bad access to renal transplantation, despite national priority programs and active desensitization protocols. After having noticed that some HLA antibodies decreased…
2018 American Transplant Congress
Immunogenic HLA Mismatches and Evidence That Belatacept May Be the First Therapy Able to Prevent DQ De Novo DSA: An Analysis of the BENEFIT and BENEFIT-EXT Trial Cohorts
M. Everly,¹ V. Jucaud,¹ M. Roberts,² H. Gebel,³ R. Bray.³
¹Terasaki Research Institute, Los Angeles, CA; ²Immunology Biomarker Group, Bristol-Myers Squibb, Princeton, NJ; ³Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
The use of belatacept over cyclosporine is associated with lower rates of DSA development in adult kidney transplantation. However, the effect of belatacept on the…
2018 American Transplant Congress
Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation
A. Vo, E. Huang, N. Ammerman, S. Williamson, C. Myers, A. Peng, R. Najjar, S. Sethi, K. Lim, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…
2018 American Transplant Congress
C1q-Binding Donor-Specific Anti-HLA Antibodies for Clinical Decision Making in Kidney Recipients with Antibody-Mediated Rejection Receiving Standard of Care Treatment
C. Lefaucheur,¹ D. Viglietti,¹ Y. Bouatou,¹ O. Aubert,¹ A. Zeevi,² A. Loupy.¹
¹Paris Translational Research Center for Organ Transplantation, Paris, France; ²University of Pittsburgh Medical Center, Pittsburgh.
One of the major issues in the clinical management of kidney recipients with ABMR is the lack of early and reliable markers that surrogate long-term…
2018 American Transplant Congress
An In Vitro Model of Human Antibody-Mediated Rejection Depicts Key Role for NK Cells
L. Hidalgo,¹ M. Racape,² A. Loupy,² C. Lefaucheur.²
¹Lab. Med. and Pathology, University of Alberta, Edmonton, AB, Canada; ²Paris Cardiovascular Research Center INSERM, Paris, France.
AIM: Antibody-mediated rejection (ABMR) is the leading cause of kidney allograft loss but its immune mechanisms are incompletely understood. We sought to examine key interactions…
2018 American Transplant Congress
Flow DSA-XM: Better Crossmatch or Just Different Problems?
P. Kimball, F. McDougan.
Surgery, VCUHealth Systems, Richmond, VA.
Background. Despite the positive impact of flow crossmatching(FCXM) upon alloantibody detection, its inability to distinguish anti-Class I from Class II or non-HLA from HLA-antibodies remain…
2018 American Transplant Congress
Time in Therapeutic Range Predicts DSA Development and Acute Rejection in Kidney Recipients with High Tacrolimus Coefficient of Variation
S. Davis, J. Gralla, P. Klem, A. Wiseman, J. Cooper.
University of Colorado, Aurora, CO.
High tacrolimus trough coefficient of variation (TAC CV) has been associated with an increased risk of de novo donor-specific antibody (dnDSA) and acute rejection (AR).…
2018 American Transplant Congress
Subclass Distribution of DSA Analyzed by Mass Spectrometry Predicts the Risk of Humoral Rejection
V. Pernin,^1,2 N. Bec,³ C. Larroque,³ C. Duperray,² G. Mourad,¹ M. Lequintrec.^1,2
¹Department of Nephrology, Dialysis and Kidney Transplantation, CHU Lapeyronie, Montpellier, France; ²INSERM U1183 Institute for Regenerative Medicine & Biotherapy (IRMB), Montpellier, France; ³Institut de Recherche en Cancérologie de Montpellier (IRCM)- CRLC Val d'Aurelle - Paul Lamarque - INSERM U896, Montpellier, France.
Background :DSA occurrence after kidney transplant is a main risk factor for humoral rejection and graft loss, however graft outcomes after DSA detection is very…